Sean P. Bohen
President, CEO & DirectorDr. Sean P. Bohen, M.D., Ph.D. has been a Director at AltruBio, Inc. He is the Chief Executive Officer and Director of Olema Oncology, Inc. (formerly known as Olema Pharmaceuticals, Inc.) since September 2020 and serves as its President and also served as its Interim Principal Financial Officer since January 30, 2026 and also served as its Chief Financial Officer. He serves as Director of Gyroscope Therapeutics Limited. Dr. Bohen is a Non-Executive Director of Gyroscope Therapeutics Holdings Limited since September 2020. Dr. Bohen is a Non-Executive Director of Gyroscope Therapeutics, Ltd. since September 2020 and AltruBio, Inc. since August 2019. Previously, he was on the Board of Transcelerate BioPharma. He had been Executive Vice President of Global Medicines Development and Chief Medical Officer at AstraZeneca PLC from September 15, 2015 to April 2019. Dr. Bohen is responsible for driving the progress of AstraZeneca's portfolio of small molecules and biologics investigational medicines through late-stage development to regulatory approval. As Chief Medical Officer, he is responsible for patient safety across the entire AstraZeneca and Medimmune portfolio. He served as Senior Vice President of Early Development at Genentech, Inc. from June 2003 to July 2015. Dr. Bohen served as Vice President of Early Development of Genentech Inc. He served as Vice President of Immunology Development, Tissue Growth & Repair and Vice President of Immunology of Genentech Inc. He oversaw preclinical and clinical development programs across all therapy areas, including oncology, respiratory and autoimmune diseases, to deliver trial-ready drug candidates to late-stage development. Earlier at Genentech, he held the positions of Senior Director of ITGR Exploratory Clinical Development, Associate Director of Oncology Exploratory Clinical Development and Assistant Medical Director of Rituxan Heme/Onc. Prior to, he held a number of positions in early and late-stage development, played a key role in the growth and progress of the Genentech/Roche portfolio. Dr. Bohen was instrumental in bringing a large number of new medicines to patients, in particular for cancer and led activities to incorporate diagnostics into clinical programs. Prior to joining Genentech, he served as an Adjunct Clinical Instructor in Oncology at Stanford University School of Medicine from October 2002 to December 2011. He is a tremendous Scientist and an accomplished drug Developer. He is an expert in key areas of exciting pipeline, including oncology and immunology. He served as a Research Associate at the Howard Hughes Medical Institute from July 2000 to June 2003 and a Postdoctoral Fellow at the National Cancer Institute from January 1995 to December 1995. Dr. Bohen earned a B.S. in bacteriology from University of Wisconsin-Madison and later earned Ph.D. in biochemistry and Biophysics and his M.D at the University of California, San Francisco.
Positions
- Company NameOlema Oncology, Inc.Stock CodeOLMAPositionPresident, CEO & DirectorColleagues
- ITIan T. ClarkIndependent Chairperson of the Board
- SMShawnte M. MitchellChief Legal Officer & Corporate Secretary
- JOJason O’ByrneCFO, Principal Financial Officer & Accounting Officer
- DCDavid C. MylesChief Scientific Officer
- COCourtney O'KonekVice President of Corporate Communications
- FPFrank P. McCormickChairman of Scientific Advisory Board
- CMCynthia Marie ButittaIndependent Director
- SGScott GarlandIndependent Director
